A groundbreaking clinical trial has revealed that a short-term fasting-mimicking diet can significantly ease symptoms and reduce inflammation in people living with mild-to-moderate Crohn’s disease, offering fresh hope where traditional dietary advice has often fallen short. Published in Nature Medicine in January 2026, the study shows that following a structured five-day low-calorie plan just once a month leads to meaningful improvements for many patients.
Researchers at Stanford Medicine led the randomized controlled trial involving 97 adults with mild-to-moderate Crohn’s disease across the United States. Participants in the fasting-mimicking diet (FMD) group consumed a plant-based, calorie-restricted meal plan providing between 700 and 1,100 calories per day for five consecutive days each month. For the remaining days, they returned to their usual diet. The control group continued eating their normal baseline diet throughout the three-month study period.
By the end of the trial, 69.2 percent of patients in the FMD group achieved a clinical response, defined as a reduction of at least 70 points on the Crohn’s Disease Activity Index or a score of 150 or lower. In comparison, only 43.8 percent in the control group reached this milestone. Even more striking, 64.6 percent of the FMD participants entered clinical remission with minimal or no symptoms, compared to just 37.5 percent in the control group.
Beyond symptom relief, the diet delivered measurable biological benefits. Fecal calprotectin levels, a key marker of intestinal inflammation, dropped by 22 percent in the FMD group while rising slightly in the control group. Additional analyses revealed reductions in inflammatory lipid mediators and immune-related gene expression, suggesting the diet actively calms the overactive immune response characteristic of Crohn’s disease.
The fasting-mimicking diet works by temporarily shifting the body into a fasting-like metabolic state that promotes cellular repair and reduces systemic inflammation without requiring complete food abstinence. This approach, developed by longevity researcher Valter Longo, has previously shown benefits for metabolic health and aging in healthy individuals. For Crohn’s patients, the periodic nature of the protocol makes it far more sustainable than continuous restrictive diets.
Lead researchers expressed pleasant surprise at the speed and strength of the results. Many patients reported noticeable relief in abdominal pain, bowel movement frequency, and overall well-being after just a few cycles. Importantly, the diet was well-tolerated and served as an adjunct to standard medical care rather than a replacement.
While the findings are highly promising, experts emphasize that patients should not attempt the diet without medical supervision, especially those with more severe disease or nutritional concerns. Larger follow-up studies are needed to confirm long-term benefits and optimal implementation strategies.
This trial highlights a powerful new tool in the management of Crohn’s disease at a time when many patients struggle to find reliable dietary guidance. A simple five-day monthly protocol could complement medications and improve quality of life for thousands worldwide.
The results open exciting possibilities for using targeted nutrition to address chronic inflammatory conditions. As further research builds on these outcomes, the fasting-mimicking diet may soon become a recommended supportive therapy, giving patients greater control over their symptoms through accessible lifestyle changes.
